cbdMDYCBD
YCBD
About: cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Employees: 42
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.62% less ownership
Funds ownership: 3.96% [Q3] → 3.34% (-0.62%) [Q4]
6% less capital invested
Capital invested by funds: $73.5K [Q3] → $69.3K (-$4.18K) [Q4]
16% less funds holding
Funds holding: 19 [Q3] → 16 (-3) [Q4]
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for YCBD.
Financial journalist opinion
Neutral
Newsfile Corp
1 week ago
cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting
Charlotte, North Carolina--(Newsfile Corp. - April 10, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) (the "Company" or "cbdMD") one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs and emerging THC-infused seltzer brand Herbal Oasis announced today that at the Company's annual meeting of shareholders held on April 10, 2025, that its Common Stock holders and 8% Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") holders approved the automatic conversion (the "Conversion") of shares of the Company's Preferred Stock into shares of the Company's Common Stock. The Company intends to set a mandatory exchange date for the Preferred Stock in the near future (the "Mandatory Exchange Date").
Neutral
Newsfile Corp
1 week ago
cbdMD Achieves Key Milestone in UK Novel Food Regulatory Approval
FSA Publishes Safety Assessment for cbdMD's Proprietary CBD Ingredient Charlotte, North Carolina--(Newsfile Corp. - April 7, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), a leader in premium hemp-derived cannabidiol (CBD) products, proudly announces that its Novel Food dossier (RP793) has advanced to the last phase of regulatory assessment with the UK Food Standards Agency (FSA), nearing final approval. This milestone not only underscores cbdMD's commitment to safety, quality, and scientific excellence but also reflects its position as a trusted brand in the growing CBD market, offering consumers confidence in purchasing compliant and rigorously tested products.
Neutral
Seeking Alpha
2 months ago
cbdMD, Inc. (YCBD) Q1 2025 Earnings Call Transcript
cbdMD, Inc. (NYSE:YCBD ) Q1 2025 Earnings Conference Call February 13, 2025 4:20 PM ET Company Participants Brad Whitford - Chief Accounting Officer Ronan Kennedy - Interim Chief Executive Officer and Chief Financial Officer Conference Call Participants Adam Waldo - Lismore Partners, LLC Thomas McGovern - Maxim Group Operator Good afternoon. Welcome to the cbdMD, Inc.'s December 31, 2024, First Fiscal Quarter of 2025 Earnings Call and Update.
Neutral
Newsfile Corp
2 months ago
cbdMD Generates $5.1 Million in Revenue, Positive Earnings
Charlotte, North Carolina--(Newsfile Corp. - February 13, 2025) - (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the first quarter of fiscal year ended December 31, 2024. The Company started fiscal 2025 with a historic quarter, achieving sequential revenue growth, positive net income and, although a loss from operations, the first ever quarter of positive non-GAAP Adjusted EBITDA.
Neutral
Newsfile Corp
2 months ago
cbdMD, Inc. to Host Conference Call to Discuss December 31, 2024 First Quarter of Fiscal Year 2025 Results
Charlotte, North Carolina--(Newsfile Corp. - February 7, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Thursday, February 13, 2025, to discuss the company's December 31, 2024 first quarter of fiscal year 2025 financial results and business progress.
Neutral
Newsfile Corp
3 months ago
cbdMD Announces It Has Fully Satisfied Its Notes
Charlotte, North Carolina--(Newsfile Corp. - January 15, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that the Company has fully satisfied the accrued interest and principal associated with its Senior Secured Convertible Notes. As of January 14, 2025, there are 6,262,833 shares of the Company's common stock issued and outstanding.
Neutral
Newsfile Corp
3 months ago
cbdMD Announces Additional Conversions of Its Convertible Notes
Charlotte, North Carolina--(Newsfile Corp. - January 8, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that the Company has reduced the principal amount outstanding on its Senior Secured Convertible Notes to approximately $56,000 as of January 8, 2025 as certain holders of the notes have converted amounts under the notes. Since the start of the year, the Company has issued an aggregate of 609,717 shares of common stock as a result of conversion requests and the aggregate balances under the notes have been reduced by approximately $309,000 of principal in addition to accrued interest.
Neutral
Newsfile Corp
3 months ago
cbdMD, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standard
Charlotte, North Carolina--(Newsfile Corp. - January 3, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) ,one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated December 31, 2024, notifying the Company that it is no longer in compliance with an additional NYSE American continued listing standard. Specifically, the letter states that the Company is not in compliance with the continued listing standard set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide").
Neutral
Newsfile Corp
3 months ago
cbdMD Announces Company's CEO Joins the Board of Directors
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that T. Ronan Kennedy, the Company's Chief Executive Officer and Chief Financial Officer, has been appointed to its Board of Directors.
Neutral
Newsfile Corp
3 months ago
cbdMD Generates $19.1 Million in Year Over Year Reduction in Net Loss Improvement
Finishes the year with a stronger cash position. Charlotte, North Carolina--(Newsfile Corp. - December 18, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the full fiscal year ended September 30, 2024.
Charts implemented using Lightweight Charts™